{"id":389838,"date":"2022-05-05T00:00:00","date_gmt":"2022-05-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0014-2022-biopharma-bladder-cancer-current-treatment-physician-insights-us-2022\/"},"modified":"2026-03-31T10:39:36","modified_gmt":"2026-03-31T10:39:36","slug":"cutron0014-2022-biopharma-bladder-cancer-current-treatment-physician-insights-us-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0014-2022-biopharma-bladder-cancer-current-treatment-physician-insights-us-2022\/","title":{"rendered":"Bladder Cancer | Current Treatment: Physician Insights | US | 2022"},"content":{"rendered":"<p>Since the approval of immune checkpoint inhibitors, the treatment of bladder cancer has been transformed. Keytruda (Merck &#038; Co.) and Opdivo (Bristol Myers Squibb) are now options in earlier settings, and Merck KGaA \/ Pfizer\u2019s Bavencio will continue to be used in the first-line maintenance setting. The approval of novel drug classes for locally advanced unresectable or metastatic disease, such as Janssen\u2019s first-in-class FGFR inhibitor Balversa (erdafitinib) for patients harboring susceptible FGFR2 or FGFR3 genetic alterations, and of antibody-drug conjugates (ADCs), such as Astellas \/ Seagen\u2019s Padcev<br \/>\n(enfortumab vedotin-ejfv) and Gilead Sciences\u2019 Trodelvy (sacituzumab govitecan), are further expanding physicians\u2019 armamentarium and reshaping the treatment of bladder cancer.<\/p>\n<p>\n<strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What percentage of high-risk non-muscle-invasive bladder cancer patients unresponsive to BCG receive Keytruda, and what is the treatment duration?<\/li>\n<li>\u00a0How do drug-treatment rates vary across key patient populations and treatment lines?<\/li>\n<li>What is the uptake of immune checkpoint inhibitors in the United States across therapy lines? How are immune checkpoint inhibitors faring against older (e.g., platinum-based chemotherapy) and newer therapies (e.g.,Balversa, Padcev, Trodelvy)?<\/li>\n<li>What clinical factors drive the use of Bavencio as a first-line maintenance therapy for unresectable locally advanced or metastatic disease?<\/li>\n<li>What are the main drivers of and obstacles to treatment with key drugs for unresectable locally advanced or metastatic bladder cancer?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><br \/>\nCurrent Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behaviour, and drivers of brand use so that marketers can create specific messaging around these treatment<br \/>\ndynamics to more effectively increase or defend their market position.<\/p>\n","protected":false},"template":"","class_list":["post-389838","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-bladder-cancer","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389838","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389838\/revisions"}],"predecessor-version":[{"id":576250,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389838\/revisions\/576250"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389838"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}